ÇãÁØ(Huh June) - ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
Abstract
Long QT syndrome (LQTS) is a well-known inheritable channelopathy that causes fatal ventricular arrhythmias. With the advancement of genetic science, the treatment of LQTS has become a paradigm for the use of genetic information inclinical practice. LQTS can present with incomplete penetrance and variable expressivity. Ten percent of silent carriers of a disease-causing mutation usually experienced symptoms when they were treated with QT-prolonging drugs. Patients with LQTS and multiple mutations have a greater risk for life-threatening cardiac events than do patients with a single mutation. LQTS tends to be easily overdiagnosed because of overlapping of a corrected QT interval (QTc), the range between normal valuesand LQTS, and lack of complete diagnostic criteria. The first line of treatment for all patients is ¥â-blocker therapy. Left cardiothoracic sympathetic denervation (LCSD) may be a therapeutic adjunct for young patients with LQTS who are not fully protected by ¥â-blocker therapy. In patients with recurrent symptoms during therapy or in those at high risk for arrhythmias, an implantable cardioverter-defibrillator (ICD) should be considered. The most important aspect of the treatment of LQTS is to determine whether the patient is at high or low risk for life-threatening arrhythmias, so that treatment can be tailored accordingly on an individual basis, more or less aggressively
Å°¿öµå
adrenergic beta-antagonists, defibrillators, genetic diseases, implantable, inborn, left cardiothoracic sympathetic denervation, long QT syndrome
KMID :
1011920130140040006
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
In patients with recurrent symptoms during therapy or in those at high risk for arrhythmias, an implantable cardioverter-defibrillator (ICD) should be considered.